Koyfin Home > Directory > Health Care > Adma Biologics > Long-Term Debt

Adma Biologics Long-Term Debt Chart (ADMA)

Adma Biologics annual/quarterly Long-Term Debt from 2010 to 2020.
  • Adma Biologics Long-Term Debt for the quarter ending June 06, 2020 was $97m a 14.33% increase of 14m year over year
  • Adma Biologics Long-Term Debt for the last 12 months ending June 06, 2020 was $97m a 14.33% increase of 14m year over year
  • Adma Biologics Annual Long-Term Debt for 2019 was $83m a 50.34% increase of 42m from 2018
  • Adma Biologics Annual Long-Term Debt for 2018 was $41m a 2.67% increase of 1m from 2017
  • Adma Biologics Annual Long-Term Debt for 2017 was $40m a 69.36% increase of 28m from 2016
Other Cash Flow Metrics:
  • Adma Biologics Cash Flow from Operations for the quarter ending December 12, 2018 was $-19m a 12.55% decrease of -2m year over year
  • Adma Biologics Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $-14m a 28.03% decrease of -4m year over year
  • Adma Biologics Total Revenue for the quarter ending September 09, 2018 was $4m a -183.74% decrease of -8m year over year
View Chart On Koyfin

Quarterly ADMA Long-Term Debt Data

06/2020$97m
03/2020$96m
12/2019$83m
09/2019$83m
06/2019$82m
03/2019$56m
12/2018$41m
09/2018$41m
06/2018$41m
03/2018$40m

Annual ADMA Long-Term Debt Data

2019$83m
2018$41m
2017$40m
2016$12m
2015$14m
2014$15m
2013$5m
2012$4m
2011$0m
2010$0m